Aspen Neuroscience Launches Cohort 3 of ASPIRO Trial for Parkinson's Disease Therapy
Aspen Neuroscience, Inc. has launched Cohort 3 of its ASPIRO Phase 1/2a clinical trial for ANPD001, an innovative therapy for Parkinson's disease. This trial evaluates the safety and preliminary efficacy of ANPD001 in levodopa-responsive patients aged 50-70, with primary endpoints reported at 12 months.
ANPD001 is an autologous induced pluripotent stem cell-derived dopaminergic neuronal precursor cell therapy. It avoids immune rejection and offers tailored treatment, positioning it uniquely in the Parkinson's therapist near me landscape. Aspen's approach includes three pillars of innovation: a proprietary manufacturing platform, a therapeutic platform using the patient's own cells, and a precision delivery system for cell transplantation.
Cohort 3 uses a commercial formulation of ANPD001 designed for scalable, reproducible manufacturing and future commercial use. This new formulation allows for immediate dosing upon arrival to the institution, streamlining surgical workflow. ANPD001 has received Fast Track designation by the U.S. Food & Drug Administration (FDA). Funding for Cohort 3 was provided by Aspen Neuroscience, Inc., while Cohorts 1 and 2 were funded by the California Institute for Regenerative Medicine (CIRM).
The initiation of Cohort 3 in the ASPIRO trial marks a significant step in the development of ANPD001 as a potential new therapy for Parkinson's disease. With its unique approach and innovative formulation, ANPD001 offers hope for tailored, effective treatment with minimal immune rejection.
Read also:
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
- Accusations of poor care and supposedly poor hygienic standards at LaSalle Hospital
